"Bupropion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.
| Descriptor ID |
D016642
|
| MeSH Number(s) |
D02.522.818.110
|
| Concept/Terms |
Bupropion- Bupropion
- Amfebutamone
- (+-)-1-(3-Chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
|
Below are MeSH descriptors whose meaning is more general than "Bupropion".
Below are MeSH descriptors whose meaning is more specific than "Bupropion".
This graph shows the total number of publications written about "Bupropion" by people in this website by year, and whether "Bupropion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 1 | 3 | 4 |
| 2010 | 1 | 0 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bupropion" by people in Profiles.
-
Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence? Nicotine Tob Res. 2019 08 19; 21(9):1289-1293.
-
Management of severe bupropion poisoning with intravenous lipid emulsion. Clin Toxicol (Phila). 2018 Jan; 56(1):51-54.
-
Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction. 2017 Aug; 112(8):1451-1459.
-
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016 Mar 08; 315(10):990-1004.
-
Commentary on Chen et?al. (2014): another step on the road to clinical utility of pharmacogenetics for smoking cessation? Addiction. 2014 Jan; 109(1):138-9.
-
Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry. 2013 Dec; 170(12):1460-7.
-
Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction. 2013 Dec; 108(12):2202-11.
-
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv. 2013 Apr 01; 64(4):339-46.
-
Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012 Feb; 12(1):86-92.
-
Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence. Nebr Symp Motiv. 2009; 55:31-63.